Nerai pioneers novel highly personalized CRISPR proteins to deliver lifelong cures for diseases beyond the reach of current genome editing. By fusing AI with programmable biology, its editors redefine what is achievable in the safety, efficiency, and targetability of genetic medicine. With lead programs targeting multi-billion markets in rare liver and eye disease and strong biopharma traction for its platform technology, Nerai is poised to become a key European-based player in vivo genome editing.
News
Milestones/News
